Company Overview

Cue Biopharma, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies designed to selectively modulate disease-relevant T cells. The company operates within the biotechnology and immuno-oncology industries, with additional research activity in autoimmune and inflammatory diseases. Cue Biopharma’s core technology platform, known as the Immuno-STAT platform, is engineered to mimic the body’s natural immune signaling mechanisms in order to activate or regulate specific T-cell populations while potentially reducing systemic toxicity associated with broader immune therapies.

The company’s primary business activities center on the research, development, and commercialization potential of its biologic drug candidates. Its lead programs have historically focused on oncology indications, including human papillomavirus (HPV)-related cancers, while additional programs target autoimmune diseases and other immune-mediated conditions. Cue Biopharma was founded in 2014 and became publicly traded on Nasdaq under the ticker CUE in 2018. The company has positioned itself as a precision immunotherapy developer aiming to differentiate its therapies through selective immune activation and modular biologic engineering.

Business Operations

Cue Biopharma organizes its operations primarily around the development of proprietary therapeutic candidates derived from its Immuno-STAT platform. The company generates revenue principally through collaboration agreements, licensing arrangements, research funding, and, to date, limited product-related revenue due to its clinical-stage status. Programs within its oncology portfolio have included candidates designed to activate tumor-specific T cells, while additional development efforts target autoimmune disorders through selective immune modulation. The company’s operations include preclinical research, clinical development, regulatory activities, and manufacturing coordination for biologic therapies.

The company operates primarily in the United States, with headquarters in Boston, Massachusetts, while also engaging with international research organizations, manufacturing providers, and clinical trial sites. Cue Biopharma has entered into strategic collaborations with larger pharmaceutical companies and research institutions to support development and commercialization efforts. Historically, partnerships have included collaborations involving immunotherapy research and biologic development capabilities. The company’s principal assets include its proprietary biologic engineering platform, intellectual property portfolio, and clinical-stage therapeutic pipeline.

Strategic Position & Investments

Cue Biopharma’s strategic direction centers on advancing selective immune modulation technologies intended to improve therapeutic efficacy while limiting unwanted immune-related adverse effects. The company has focused investment toward expanding and validating the Immuno-STAT platform across oncology and autoimmune disease applications. Clinical development initiatives have included advancing lead oncology candidates through early- and mid-stage clinical studies while exploring broader applications of antigen-specific immune modulation.

The company has also pursued strategic collaborations intended to provide external validation, development support, and potential commercialization pathways. These collaborations have included relationships with major pharmaceutical and biotechnology organizations focused on immunotherapy innovation. Cue Biopharma continues to invest in translational research, biologic engineering, and next-generation immunotherapy technologies that may support future pipeline expansion. Public filings and corporate disclosures indicate ongoing prioritization of capital allocation toward clinical advancement and platform-based therapeutic development.

Geographic Footprint

Cue Biopharma’s primary operational base is located in Boston, Massachusetts, within the broader United States biotechnology sector. Its clinical development and research activities are concentrated primarily in North America, though the company’s collaborations, manufacturing relationships, and clinical trial infrastructure involve international participants. The company’s therapies are designed for global therapeutic markets, particularly in oncology and autoimmune disease treatment segments.

The company maintains a relatively focused geographic footprint compared with large multinational pharmaceutical firms, but its strategic partnerships and clinical programs provide exposure to broader international biopharmaceutical ecosystems. Clinical studies and development partnerships may involve organizations across North America and Europe, reflecting the global nature of immunotherapy development and biologic manufacturing.

Leadership & Governance

Cue Biopharma was co-founded by Daniel Passeri, who has served as a principal leader in shaping the company’s strategy around precision immunotherapy and selective immune modulation. Corporate governance and strategic oversight are guided by an executive leadership team and board with experience spanning biotechnology, immunology, pharmaceuticals, finance, and clinical development. Public company governance practices are documented through SEC filings, including annual reports and proxy statements.

Key executives associated with Cue Biopharma include:

• Daniel Passeri – Chief Executive Officer
• Anish Suri, M.D. – Chief Medical Officer
• Rodney Varner – Chief Financial Officer
• David H. Margolin, M.D., Ph.D. – President of Research and Development

Leadership strategy has emphasized platform-driven innovation, disciplined clinical development, and partnership-oriented growth intended to support long-term commercialization opportunities in immunotherapy markets.